Financial News Feed

Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The unfolding week is all about the presentations at one of the largest educational and scientific events for the oncology community. Here are the key events/catalysts to look forward to: Conferences The American Society of Clinical Oncology, or ASCO, 2019 Annual Meeting – May 31–June 4, in Chicago, Illinois The European Academy of Allergy and Clinical Immunology 2019 Annual Congress – June 1-5, in Lisbon, Portugal 20th Global Nephrologists Annual Meeting - June 3-4, in London Jefferies 2019 Healthcare Conference – June 4-7, in New York City European Society for Pediatric Gastroenterology, Hepatology and Nutrition 2019 Annual Meeting – June 5-8, in Glasgow, Scotland HBV Cure Meeting – June 7-8, in Singapore The American Diabetes Association's 79th Scientific Sessions – June 7-11, in San Francisco, California PDUFA Dates The FDA is scheduled to rule Monday on Merck & Co., Inc. (NYSE: MRK )'s sNDA for Zerbaxa (ceftolozone and tazobactam) in treating adult patients with ventilated nosocomial (hospital-acquired) pneumonia ASCO Presentations On Sunday, June 2 Aduro BioTech Inc (NASDAQ: ADRO ) – Phase 1b data for ADU-S100 and Spartalozumab (solid tumors or lymphomas) Celgene Corporation (NASDAQ: CELG ) – Phase 1/2 data on CC-220 (relapsed and/or refractory multiple myeloma) CAN-FITE BIOPHA/S ADR (NYSE: CANF ) – already-released Phase 2 data for Namodenoson (second-line treatment of advanced liver cancer) Amgen, Inc. (NASDAQ: AMGN ) – Phase 1 data for AMG 420 (relapsed, refractory multiple myeloma) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) – Phase 1 data for Ad-RTS-Hil-12 (recurrent glioblastoma) as well as initial Phase …...

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY )( reacted to the news of the initiation of cellulite trial) Eidos Therapeutics Inc (NASDAQ: EIDX ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 29) Abeona Therapeutics Inc (NASDAQ: ABEO ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) Allergan plc (NYSE: AGN ) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) Aptinyx Inc (NASDAQ: APTX ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) CAN-FITE BIOPHA/S ADR (NYSE: CANF )(reacted to its first-quarter results and an update on clinical trial progress) Cidara Therapeutics Inc (NASDAQ: CDTX ) Diplomat Pharmacy Inc (NYSE: DPLO ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Emergent Biosolutions Inc (NYSE: EBS ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Hookipa Pharma Inc (NASDAQ: HOOK ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Melinta Therapeutics Inc (NASDAQ: MLNT ) Opko Health Inc. (NASDAQ: OPK ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Seres Therapeutics Inc (NASDAQ: MCRB ) Teva Pharmaceutical Industries Ltd (NYSE: TEVA )( downgraded by UBS to Neutral on its legal woes) Theravance Biopharma Inc (NASDAQ: TBPH ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Stock In Focus Unity …...

Read more

No summary available....

Read more

No summary available....

Read more

Uber Time (Stocks To Watch Podcast)
12:00pm, Sunday, 05'th May 2019
No summary available....

Read more

No summary available....

Read more

No summary available....

Read more

Both Sutro Biopharma Inc. (NASDAQ:STRO) and Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) compete on a level playing field in the Biotechnology industry. We will...

Read more

Investors may be diving into the latest company earnings reports trying to scope out some quality stocks to add to the portfolio. Nobody knows for sure which way overall market momentum will sway as w...

Read more

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) and Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recom...

Read more

We will be comparing the differences between Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) and Ra Pharmaceuticals Inc. (NASDAQ:RARX) as far as risk, analyst recommendations, profitability, dividends, in...

Read more

HC Wainwright reaffirmed their buy rating on shares of CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) in a research report released on Wednesday, AnalystRatings.com reports. “We reiterate our Buy rating and ...

Read more

Aptinyx Inc. (NASDAQ:APTX) and Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the div...

Read more

Both Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) and Urovant Sciences Ltd. (NASDAQ:UROV) are Biotechnology companies, competing one another. We will contrast their risk, analyst recommendations, profi...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank